Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisatracurium Pretreatment for Succinylcholine-Induced Fasciculations
NCT02502032Phase 3Completed
- Start
- Jul 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of cisatracurium in fasciculation and myalgia. Primary endpoint: Presence of fasciculations. Started Jul 2015; status: completed.
02
Drugs
cisatracurium
03
Conditions
fasciculationmyalgia
Beyond the preview
Go deeper on NCT02502032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502032.